Fig. 7From: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluationPercentage of cell viability nanoformulations of VC-loaded in TCs-HA and pure VC-treated PC3 and HPrEc at a different concentration (mean ± SD, p ≤ 0.05, *** highly significant)Back to article page